FELDAN THERAPEUTICS REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATE
FLD-103 was generally well tolerated across all dose cohorts; no maximum tolerated dose was reached.
FLD-103 was generally well tolerated across all dose cohorts; no maximum tolerated dose was reached.